---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-025823"
form_type: "8-K"
ticker: "BAX"
cik: "0000010456"
company_name: "BAXTER INTERNATIONAL INC"
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-12T23:37:31.438585+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Baxter Q2 revenue beats; GAAP loss; adjusted EPS down 24%; KidneyCare spinoff named Vantive

## Summary
- Q2 continuing ops revenue $3.71B, +3% reported (+4% constant currency), above guidance.
- GAAP EPS from continuing ops ($0.39); total GAAP EPS ($0.28); adjusted total EPS $0.66, -24% YoY.
- FY23 adjusted EPS from continuing ops guidance: $2.49-$2.57 (BPS not sold) or $2.54-$2.62 (BPS sold Sept 30).
- Kidney Care spinoff to be named Vantive; Chris Toth named CEO; expected by July 2024.
- Definitive agreement to divest BioPharma Solutions to Advent/Warburg Pincus; closing expected H2 2023.

## SEC filing metadata
- accession: 0001628280-23-025823
- form_type: 8-K
- ticker: BAX
- cik: 0000010456
- company_name: BAXTER INTERNATIONAL INC
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10456/000162828023025823/0001628280-23-025823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10456/000162828023025823/bax-20230727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-025823
- JSON: https://secwatch.observer/filing/0001628280-23-025823.json
- Plain text: https://secwatch.observer/filing/0001628280-23-025823.txt

## Key facts
- Earnings Releases
  BAXTER INTERNATIONAL INC reported the second quarter of 2023 results: revenue $3.71 billion, net income ($141 million), EPS ($0.28) per diluted share.
  - Period: the second quarter of 2023
  - Revenue: $3.71 billion
  - Net income: ($141 million)
  - EPS: ($0.28) per diluted share
  - Result: reported results
  source text: an effort to drive greater value for our stakeholders.” Second-Quarter Financial Results Worldwide sales from continuing operations in the second quarter totaled approximately $3.71 billion and sales from discontinued operations totaled $142 million in the quarter. This performance represented an increase of 3% on a reported basis and 4% on a constant currency
  evidence_url: https://www.sec.gov/Archives/edgar/data/10456/000162828023025823/0001628280-23-025823-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.